Dynavax Technologies Corp
NASDAQ:DVAX

Watchlist Manager
Dynavax Technologies Corp Logo
Dynavax Technologies Corp
NASDAQ:DVAX
Watchlist
Price: 12.42 USD 0.49% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Dynavax Technologies Corp?
Write Note

Intrinsic Value

The intrinsic value of one DVAX stock under the Base Case scenario is 7.57 USD. Compared to the current market price of 12.42 USD, Dynavax Technologies Corp is Overvalued by 39%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DVAX Intrinsic Value
7.57 USD
Overvaluation 39%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Dynavax Technologies Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for DVAX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about DVAX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Dynavax Technologies Corp

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Dynavax Technologies Corp

Provide an overview of the primary business activities
of Dynavax Technologies Corp.

What unique competitive advantages
does Dynavax Technologies Corp hold over its rivals?

What risks and challenges
does Dynavax Technologies Corp face in the near future?

Has there been any significant insider trading activity
in Dynavax Technologies Corp recently?

Summarize the latest earnings call
of Dynavax Technologies Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Dynavax Technologies Corp.

Provide P/S
for Dynavax Technologies Corp.

Provide P/E
for Dynavax Technologies Corp.

Provide P/OCF
for Dynavax Technologies Corp.

Provide P/FCFE
for Dynavax Technologies Corp.

Provide P/B
for Dynavax Technologies Corp.

Provide EV/S
for Dynavax Technologies Corp.

Provide EV/GP
for Dynavax Technologies Corp.

Provide EV/EBITDA
for Dynavax Technologies Corp.

Provide EV/EBIT
for Dynavax Technologies Corp.

Provide EV/OCF
for Dynavax Technologies Corp.

Provide EV/FCFF
for Dynavax Technologies Corp.

Provide EV/IC
for Dynavax Technologies Corp.

Show me price targets
for Dynavax Technologies Corp made by professional analysts.

What are the Revenue projections
for Dynavax Technologies Corp?

How accurate were the past Revenue estimates
for Dynavax Technologies Corp?

What are the Net Income projections
for Dynavax Technologies Corp?

How accurate were the past Net Income estimates
for Dynavax Technologies Corp?

What are the EPS projections
for Dynavax Technologies Corp?

How accurate were the past EPS estimates
for Dynavax Technologies Corp?

What are the EBIT projections
for Dynavax Technologies Corp?

How accurate were the past EBIT estimates
for Dynavax Technologies Corp?

Compare the revenue forecasts
for Dynavax Technologies Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Dynavax Technologies Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Dynavax Technologies Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Dynavax Technologies Corp compared to its peers.

Compare the P/E ratios
of Dynavax Technologies Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Dynavax Technologies Corp with its peers.

Analyze the financial leverage
of Dynavax Technologies Corp compared to its main competitors.

Show all profitability ratios
for Dynavax Technologies Corp.

Provide ROE
for Dynavax Technologies Corp.

Provide ROA
for Dynavax Technologies Corp.

Provide ROIC
for Dynavax Technologies Corp.

Provide ROCE
for Dynavax Technologies Corp.

Provide Gross Margin
for Dynavax Technologies Corp.

Provide Operating Margin
for Dynavax Technologies Corp.

Provide Net Margin
for Dynavax Technologies Corp.

Provide FCF Margin
for Dynavax Technologies Corp.

Show all solvency ratios
for Dynavax Technologies Corp.

Provide D/E Ratio
for Dynavax Technologies Corp.

Provide D/A Ratio
for Dynavax Technologies Corp.

Provide Interest Coverage Ratio
for Dynavax Technologies Corp.

Provide Altman Z-Score Ratio
for Dynavax Technologies Corp.

Provide Quick Ratio
for Dynavax Technologies Corp.

Provide Current Ratio
for Dynavax Technologies Corp.

Provide Cash Ratio
for Dynavax Technologies Corp.

What is the historical Revenue growth
over the last 5 years for Dynavax Technologies Corp?

What is the historical Net Income growth
over the last 5 years for Dynavax Technologies Corp?

What is the current Free Cash Flow
of Dynavax Technologies Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Dynavax Technologies Corp.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Dynavax Technologies Corp

Current Assets 926.2m
Cash & Short-Term Investments 764m
Receivables 75.3m
Other Current Assets 87m
Non-Current Assets 135.7m
PP&E 59.2m
Intangibles 2.1m
Other Non-Current Assets 74.5m
Current Liabilities 70m
Accounts Payable 7.1m
Accrued Liabilities 62.9m
Other Current Liabilities 14k
Non-Current Liabilities 310.5m
Long-Term Debt 223.6m
Other Non-Current Liabilities 87m
Efficiency

Earnings Waterfall
Dynavax Technologies Corp

Revenue
260.8m USD
Cost of Revenue
-44.7m USD
Gross Profit
216.1m USD
Operating Expenses
-223.5m USD
Operating Income
-7.4m USD
Other Expenses
27.9m USD
Net Income
20.5m USD

Free Cash Flow Analysis
Dynavax Technologies Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

DVAX Profitability Score
Profitability Due Diligence

Dynavax Technologies Corp's profitability score is 65/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Positive Gross Profit
Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
65/100
Profitability
Score

Dynavax Technologies Corp's profitability score is 65/100. The higher the profitability score, the more profitable the company is.

DVAX Solvency Score
Solvency Due Diligence

Dynavax Technologies Corp's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
55/100
Solvency
Score

Dynavax Technologies Corp's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DVAX Price Targets Summary
Dynavax Technologies Corp

Wall Street analysts forecast DVAX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DVAX is 24.28 USD with a low forecast of 15.15 USD and a high forecast of 30.45 USD.

Lowest
Price Target
15.15 USD
22% Upside
Average
Price Target
24.28 USD
95% Upside
Highest
Price Target
30.45 USD
145% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for DVAX?

Click here to dive deeper.

Dividends

Dynavax Technologies Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for DVAX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

DVAX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Dynavax Technologies Corp Logo
Dynavax Technologies Corp

Country

United States of America

Industry

Biotechnology

Market Cap

1.6B USD

Dividend Yield

0%

Description

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 311 full-time employees. The company went IPO on 2004-02-19. The firm's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The firm also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The firm is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). The company is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.

Contact

CALIFORNIA
Emeryville
2100 Powell Street, Suite 900
+15108485100.0
www.dynavax.com

IPO

2004-02-19

Employees

311

Officers

CEO & Director
Mr. Ryan Spencer
President & COO
Mr. David F. Novack
Senior VP & CFO
Ms. Kelly MacDonald
Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs
Dr. Robert Janssen M.D.
Chief Accounting Officer & Controller
Mr. Justin Burgess
Senior VP & Chief Human Resources Officer
Mr. Jeff P. Coon
Show More
VP of Investor Relations & Corporate Communications
Mr. Paul Cox
Senior VP & General Counsel
Mr. John L. Slebir
Senior VP & Chief Commercial Officer
Mr. Donn Casale
Senior Vice President of Vaccine Research
Dr. Dong Yu
Show Less

See Also

Discover More
What is the Intrinsic Value of one DVAX stock?

The intrinsic value of one DVAX stock under the Base Case scenario is 7.57 USD.

Is DVAX stock undervalued or overvalued?

Compared to the current market price of 12.42 USD, Dynavax Technologies Corp is Overvalued by 39%.

Back to Top